Progenics Pharmaceuticals, an oncology company developing medicines and imaging analytical tools for targeting and treating cancer, announced today that the FDA has accepted for review the New Drug Application (NDA) for Azerda in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors. The FDA granted Progenics’ request for Priority Review and has set…
FDA Accepts New Drug Application For Treatment Of Rare Neuroendocrine Tumors
Progenics Pharmaceuticals announces FDA acceptance of New Drug Application for Azedra (iobenguane I 131) in pheochromocytoma and paraganglioma. Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Azedra in…